Key facts
- This page summarizes Gregory Gene Freitag's Form 4 filing for Axogen, Inc. (AXGN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Sep 2023, 06:28.
Gregory Gene Freitag - 01 Sep 2023 Form 4 Insider Report for Axogen, Inc. (AXGN)
- Reporting relationship
- Director
- Issuer ticker
- AXGN
- Reported as of
- 01 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Sep 2023, 06:28:11 UTC
- Prior SEC filing
- 17 Jul 2023
- Next SEC filing
- 08 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/Gregory Freitag
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gregory Gene Freitag filed Form 4 for Axogen, Inc. (AXGN) on 07 Sep 2023.
Change
- Previous filing in this sequence was filed on 17 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXGN
transaction
Derivative
Stock Option (right to purchase)
Award
- Transaction value
- $0
- Shares
- +20,436
- Change %
- Price
- $0.000000
- Shares after
- 20,436
- Date
- 01 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,436
- Exercise price
- $6.30
- Footnotes
- F1
AXGN
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +11,904
- Change %
- Price
- $0.000000
- Shares after
- 11,904
- Date
- 01 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,904
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.